Engineered immune cells target stubborn abdominal cancer
NCT ID NCT07247396
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a personalized cell therapy (CAR-T cells) designed to attack a protein called CEA found on colorectal cancer cells. The therapy is given directly into the abdomen after surgery to remove visible tumors. The study will enroll 12 adults whose cancer has spread to the belly lining and who have not responded to standard treatments. The main goals are to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CEA-targeted CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced colorectal cancer that has spread to the lining of the abdomen.
- What could go wrong
- This is a very early (Phase 1) trial with only 12 people, so it is mainly checking safety and dosing. The therapy may not shrink tumors or improve survival, and side effects like cytokine release syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER WITH PERITONEAL METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310017, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.